2162 — Keymed Biosciences Share Price
0.000.00%
Last trade - 00:00- HK$7.60bn
- HK$5.11bn
- CNY354.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.35 | ||
| Price to Tang. Book | 2.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.36% | ||
| Return on Equity | -11.36% | ||
| Operating Margin | -94.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 110.27 | 100.06 | 354.1 | 115.58 | 547.62 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 23rd, 2018
- Public Since
- July 8th, 2021
- No. of Employees
- 897
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 276,695,566
- Address
- 18 Biotown Middle Road Building D2, CHENGDU, 610219
- Web
- https://www.keymedbio.com/
- Phone
- Auditors
- Ernst & Young
Upcoming Events for 2162
KeyMed Biosciences Inc Annual Shareholders Meeting
Half Year 2024 KeyMed Biosciences Inc Earnings Release
Similar to 2162
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Keymed Biosciences share price?
As of Today at 19:12 UTC, shares in Keymed Biosciences are trading at HK$27.45. This share price information is delayed by 15 minutes.
How has the Keymed Biosciences share price performed this year?
Shares in Keymed Biosciences last closed at HK$27.45 and the price had moved by -56.97% over the past 365 days. In terms of relative price strength the Keymed Biosciences share price has underperformed the FTSE Developed Asia Pacific Index by -55.09% over the past year.
What are the analyst and broker recommendations for Keymed Biosciences?
The overall consensus recommendation for Keymed Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Keymed Biosciences dividend yield?
Keymed Biosciences does not currently pay a dividend.
Does Keymed Biosciences pay a dividend?
Keymed Biosciences does not currently pay a dividend.
When does Keymed Biosciences next pay dividends?
Keymed Biosciences does not currently pay a dividend.
How do I buy Keymed Biosciences shares?
To buy shares in Keymed Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Keymed Biosciences?
As of the previous close price of HK$27.45, shares in Keymed Biosciences had a market capitalisation of HK$7.60bn.
Where are Keymed Biosciences shares listed?
Here are the trading details for Keymed Biosciences:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2162
What kind of share is Keymed Biosciences?
Based on an overall assessment of its quality, value and momentum Keymed Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Keymed Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Keymed Biosciences is HK$61.24. That is 123.1% above the last closing price of HK$27.45.
Analysts covering Keymed Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -CNY2.95 for the next financial year.
What is the trend in the Keymed Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Keymed Biosciences. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -52.29%.
As of the last closing price of HK$27.45, shares in Keymed Biosciences were trading -39.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Keymed Biosciences PE Ratio?
The Keymed Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$27.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Keymed Biosciences?
We do not have data on Keymed Biosciences' directors